Investors Encouraged to Join PepGen Inc. Securities Fraud Class Action Lawsuit

The Schall Law Firm, which specializes in shareholder rights litigation, has recently announced an opportunity for investors in PepGen Inc. to join a class action lawsuit. This legal action arises from significant allegations made against PepGen regarding its securities and practices within the market.

Background on PepGen Inc.

PepGen Inc., trading on the NASDAQ under the symbol PEPG, is a biotechnology company focused on developing innovative treatments. However, concerns have emerged regarding the validity of the company's public statements regarding the safety and efficacy of its drug candidate, PGN-EDO51. Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, are crucial to the ongoing investigation of the company's practices.

The Allegations

The allegations suggest that PepGen made misleading statements to the market, suggesting that its drug candidate was safe and effective, despite evidence to the contrary. According to the class action complaint, the CONNECT2 clinical study was inadequately designed for FDA approval and posed safety risks to participants. This deficiency raises serious questions about the integrity of the data presented to Invest-potential investors.

As the company faces scrutiny, it is understood that there was potential for the CONNECT2 study to be halted, leading to a severe blow to the company’s reputation and investor confidence. Investors are encouraged to act promptly, as the deadline to join the lawsuit is approaching on August 8, 2025.

Why Join the Class Action Lawsuit?

Participating in the class action lawsuit gives investors a chance to recover losses incurred during the alleged fraud. Those who have experienced negative financial impacts due to PepGen's actions should consider this opportunity seriously. The Schall Law Firm is offering free consultations for affected shareholders, which can help clarify the next steps and outline potential rights and claims.

How to Get Involved

If you are one of the shareholders who believe they have suffered financial losses tied to PepGen, you can reach out to Brian Schall and his team at the Schall Law Firm. They are located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, and can be contacted at 310-301-3335. The firm also maintains a user-friendly website at www.schallfirm.com, where affected investors can acquire more information about joining the lawsuit and protecting their rights.

Call to Action

This is a pivotal moment for PepGen investors, as the outcome of this class action lawsuit could set a precedent for accountability in the pharmaceutical and biotechnology sectors. As information continues to unfold regarding the allegations against PepGen, it is essential for investors to stay informed and actively participate in being part of this collective legal action. Joining together increases the voices calling for justice and accountability from the company.

In summary, potential investors who purchased PepGen’s securities during the stated period should actively consider joining this class-action lawsuit. The Schall Law Firm remains a dedicated resource for shareholders aiming to recover their investments and hold companies accountable for misinformation and safety protocols.